{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ASV", "query": { "intervention": "ASV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ASV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T04:38:24.210Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01128816", "title": "Effect of Adaptive Servo Ventilation (ASV) on Survival and Hospital Admissions in Heart Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep Apnea", "Heart Failure" ], "interventions": [ { "name": "Adaptive Servo Ventilation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Toronto Rehabilitation Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 732, "start_date": "2010-05", "completion_date": "2022-03-31", "has_results": false, "last_update_posted_date": "2022-11-22", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 3, "location_summary": "Tucson, Arizona • Kalispell, Montana • Cleveland, Ohio", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Kalispell", "state": "Montana" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01128816" }, { "nct_id": "NCT03195660", "title": "Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure With Normal Ejection Fraction", "Sleep Apnea" ], "interventions": [ { "name": "ASV Therapy", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "ResMed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2017-06-26", "completion_date": "2017-11-15", "has_results": true, "last_update_posted_date": "2021-05-14", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 3, "location_summary": "San Diego, California • Philadelphia, Pennsylvania • Falls Church, Virginia", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03195660" }, { "nct_id": "NCT02175966", "title": "Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV/ASV/BMS-791325", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Sofosbuvir", "type": "DRUG" }, { "name": "Peginterferon α-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 35, "start_date": "2014-07-28", "completion_date": "2015-12-17", "has_results": true, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 7, "location_summary": "Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Rialto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02175966" }, { "nct_id": "NCT01581203", "title": "Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "Asunaprevir (ASV)", "type": "DRUG" }, { "name": "Daclatasvir (DCV)", "type": "DRUG" }, { "name": "Pegylated-interferon alfa 2a (PegIFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 748, "start_date": "2012-05", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 18, "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01581203" }, { "nct_id": "NCT01030432", "title": "Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-650032", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 285, "start_date": "2010-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Orlando, Florida + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030432" }, { "nct_id": "NCT01309932", "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Lambda (pegIFNλ)", "type": "BIOLOGICAL" }, { "name": "BMS-790052 (NS5A Inhibitor)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "BMS-650032 (NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a (pegIFNα-2a)", "type": "BIOLOGICAL" }, { "name": "Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)", "type": "DRUG" }, { "name": "Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)", "type": "DRUG" }, { "name": "Placebo for Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2011-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palm Springs", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lutherville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01309932" }, { "nct_id": "NCT02365064", "title": "CPAP vs ASV for Insomnia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Insomnia", "Sleep-Disordered Breathing" ], "interventions": [ { "name": "AirCurve 10 ASV", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "ResMed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-02", "completion_date": "2017-12-01", "has_results": true, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365064" }, { "nct_id": "NCT02992977", "title": "Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "AutoSynVax™ vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-01", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 2, "location_summary": "Miami, Florida • Columbus, Ohio", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02992977" }, { "nct_id": "NCT01795911", "title": "Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Lambda", "type": "BIOLOGICAL" }, { "name": "Ribasphere", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2013-03", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01795911" }, { "nct_id": "NCT02108639", "title": "To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "DCV 3DAA FDC", "type": "DRUG" }, { "name": "BMS-791325", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2014-04", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-07-10", "last_synced_at": "2026-09-04T04:38:24.210Z", "location_count": 4, "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02108639" } ] }